Xponance’s Immunome IMNM Stock Holding History

Xponance’s Portfolio IMNM Stock Details IMNM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$214K	Buy	10,103 +718	+8%	+$15.4K	﹤0.01%	1580
2026 Q1	$205K	Buy	+9,385	New	+$209K	﹤0.01%	1467

Other funds holding IMNM

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return

Xponance's IMNM Position: Q2 2026 in Review

Xponance increased its Immunome (IMNM) stake by 7.7% in Q2 2026, buying an estimated $15.4K and bringing the position to 10,103 shares worth $214K. The position accounts for ﹤0.01% of the portfolio, ranked #1580.

Xponance first reported a position in IMNM in Q1 2026 and has held it in 2 quarters since. 202 funds tracked by Wall St. Rank hold IMNM as of Q2 2026.

Xponance held 10,103 shares of Immunome worth $214K as of Q2 2026.
Xponance bought 718 Immunome shares in Q2 2026, an estimated $15.4K.
Immunome made up ﹤0.01% of Xponance's portfolio in Q2 2026, its #1580 holding.
Xponance first reported a position in Immunome in Q1 2026 and has held it in 2 quarters since.
202 funds tracked by Wall St. Rank held Immunome as of Q2 2026.

Based on Xponance's 13F filing for Q2 2026, filed 10 Aug 2026.